Protein Summary
Ras proteins bind GDP/GTP and possess intrinsic GTPase activity. Plays an important role in the regulation of cell proliferation (PubMed:23698361, PubMed:22711838). Plays a role in promoting oncogenic events by inducing transcriptional silencing of tumor suppressor genes (TSGs) in colorectal cancer (CRC) cells in a ZNF304-dependent manner (PubMed:24623306). This gene, a Kirsten ras oncogene homolog from the mammalian ras gene family, encodes a protein that is a member of the small GTPase superfamily. A single amino acid substitution is responsible for an activating mutation. The transforming protein that results is implicated in various malignancies, including lung adenocarcinoma, mucinous adenoma, ductal carcinoma of the pancreas and colorectal carcinoma. Alternative splicing leads to variants encoding two isoforms that differ in the C-terminal region. [provided by RefSeq, Jul 2008]
- ENST00000256078
- ENSP00000256078
- ENSG00000133703
- ENST00000311936
- ENSP00000308495
- KRAS2
- RASK2
- NS
- NS3
- CFC2
- RALD
- K-Ras
- KRAS1
- KRAS2
- RASK2
- KI-RAS
- C-K-RAS
- K-RAS2A
- K-RAS2B
- K-RAS4A
- K-RAS4B
- c-Ki-ras2
Most Knowledge About | Knowledge Value
(0 to 1 scale) | ||
---|---|---|---|
biological process | 0.99 | ||
disease | 0.99 | ||
kinase perturbation | 0.99 | ||
phenotype | 0.98 | ||
transcription factor perturbation | 0.97 | ||
Protein Classes
IDG Development Level Summary
These are targets about which virtually nothing is known. They do not have known drug or small molecule activities
- AND - satisfy two or more of the following criteria:
Pubmed score: 8557.16 (req: < 5)
Gene RIFs: 2648 (req: <= 3)
Antibodies: 754 (req: <= 50)
These targets do not have known drug or small molecule activities
- AND - satisfy two or more of the following criteria:
Pubmed score: 8557.16 (req: >= 5)
Gene RIFs: 2648 (req: > 3)
Antibodies: 754 (req: > 50)
- OR - satisfy the following criterion:
Gene Ontology Terms: 36
Target has at least one ChEMBL compound with an activity cutoff of < 30 nM - AND - satisfies the preceding conditions
Active Ligands: 221
Target has at least one approved drug - AND - satisfies the preceding conditions
Active Drugs: 2